CN105357966A - 提高药物和膳食补充剂的生物利用度的方法和产品 - Google Patents

提高药物和膳食补充剂的生物利用度的方法和产品 Download PDF

Info

Publication number
CN105357966A
CN105357966A CN201480028482.XA CN201480028482A CN105357966A CN 105357966 A CN105357966 A CN 105357966A CN 201480028482 A CN201480028482 A CN 201480028482A CN 105357966 A CN105357966 A CN 105357966A
Authority
CN
China
Prior art keywords
dietary supplement
drug
tetrandrine family
tetrandrine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028482.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·L·巴涅特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBA Pharma Inc
Original Assignee
CBA Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBA Pharma Inc filed Critical CBA Pharma Inc
Publication of CN105357966A publication Critical patent/CN105357966A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN201480028482.XA 2013-03-15 2014-03-12 提高药物和膳食补充剂的生物利用度的方法和产品 Pending CN105357966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792700P 2013-03-15 2013-03-15
US61/792,700 2013-03-15
PCT/US2014/024592 WO2014150935A1 (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability

Publications (1)

Publication Number Publication Date
CN105357966A true CN105357966A (zh) 2016-02-24

Family

ID=51529972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028482.XA Pending CN105357966A (zh) 2013-03-15 2014-03-12 提高药物和膳食补充剂的生物利用度的方法和产品

Country Status (7)

Country Link
US (1) US9345257B2 (enExample)
EP (1) EP2986122A4 (enExample)
JP (1) JP2016514142A (enExample)
KR (1) KR20150143504A (enExample)
CN (1) CN105357966A (enExample)
MX (1) MX2015013158A (enExample)
WO (1) WO2014150935A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability
JP2016514143A (ja) * 2013-03-15 2016-05-19 シービーエー・ファーマ・インコーポレイテッドCba Pharma, Inc. 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) * 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20060030586A1 (en) * 2004-08-03 2006-02-09 Education Center Of Traditional Chinese Medicine Co. Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability
JP2016514143A (ja) * 2013-03-15 2016-05-19 シービーエー・ファーマ・インコーポレイテッドCba Pharma, Inc. 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) * 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20060030586A1 (en) * 2004-08-03 2006-02-09 Education Center Of Traditional Chinese Medicine Co. Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAO-RUI LIU ET AL: "Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on...", 《CANCER CHEMOTHERAPY AND PHARMACOLOGY 》 *
RVING LIEBERMAN ET AL: "SYNERGY BETWEEN TETRANDRINE AND FK506 IN PREVENTION OF DIABETES IN BB RATS", 《LIFE SCIENCES》 *
YOUNG-SEOB LEE ET AL: "Synergistic effect of tetrandrine and ethidium bromide against methicillin-resistant Staphylococcus aureus (MRSA)", 《THE JOURNAL OF TOXICOLOGICAL SCIENCE》 *

Also Published As

Publication number Publication date
EP2986122A4 (en) 2017-01-18
US20140275140A1 (en) 2014-09-18
JP2016514142A (ja) 2016-05-19
MX2015013158A (es) 2016-04-15
WO2014150935A1 (en) 2014-09-25
EP2986122A1 (en) 2016-02-24
US9345257B2 (en) 2016-05-24
KR20150143504A (ko) 2015-12-23

Similar Documents

Publication Publication Date Title
CA3149460C (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
JP2013509395A5 (enExample)
TWI654981B (zh) 包含度他雄胺和丙二醇單月桂酸酯的醫藥組成物及其製備方法
US20140275139A1 (en) Mdr method and products for treating hiv/aids
US20170050975A1 (en) Tetrandrine family pharmaceutical formulations and method
CN105357966A (zh) 提高药物和膳食补充剂的生物利用度的方法和产品
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
US20140073670A1 (en) Pharmaceutical composition comprising fexofenadine
CN104955330A (zh) 粉防己碱药物制剂及方法
US20140275138A1 (en) Method and products for treating diabetes
US20140073591A1 (en) Mdr method and products for treating mrsa
CN105377259A (zh) 提高药物和膳食补充剂的细胞吸收的方法和产品
JP6197515B2 (ja) 医薬組成物
JP2017515858A5 (enExample)
JP5241127B2 (ja) 鎮痛用組成物
JP2018076312A (ja) アセトアミノフェン、イソプロピルアンチピリン及びショウガ由来成分を含有する医薬組成物
JP2010077102A (ja) 高齢者向け機能食品および医薬組成物
CN117180264A (zh) 五味子乙素在制备镇痛药物中的应用
RU2540509C1 (ru) Лекарство
RU2446803C1 (ru) Лекарственное средство в виде капсул, обладающее противовирусным и интерфероногенным действием
Doshi et al. Furazolidone (Furazolidine)
KR20100054955A (ko) 세티리진이염산염을 함유하는 연질 캡슐의 조성물 및 그의 제조방법
TH84855A (th) การใช้สารผสมเซเลคอกซิบสำหรับบรรเทาอาการปวดอย่างรวดเร็ว
HK1234991B (zh) 抗癌组合物
Khirwadkar et al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF CINNARIZINE BY SUPER DISINTEGRANTS ADDITION METHOD

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224